By licensing Elsie Biotechnologies' discovery platform, GSK is likely to enhance its research and development capabilities in the oligonucleotide therapeutics area. This could lead to the development of new therapies, potentially boosting GSK's market position and future revenue streams. The strategic nature of this partnership and its focus on a specific, promising area of biotechnology suggest a positive impact on GSK's stock in the short term.